Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.47 |
| ▸ | CCR1 | P32246 | 12/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713862 | 0.93 | CAPN1 (0.58) | CAPN1 | |
| SCHEMBL2803110 | 0.85 | CAPN1 (0.66) | CAPN1 | |
| SCHEMBL2800282 | 0.79 | PYGL (0.47) | CAPN1CCR1PYGL | |
| SCHEMBL2803091 | 0.79 | ALDH1A1 (0.58) | CAPN1CCR1PYGL | |
| SCHEMBL2801618 | 0.79 | CAPN1 (0.75) | CAPN1CCR1PYGL | |
| SCHEMBL2800895 | 0.75 | KDM4E (0.57) | — | |
| SCHEMBL3711942 | 0.74 | CAPN1 (0.87) | CAPN1 | |
| SCHEMBL24008857 | 0.74 | CAPN1 (0.44) | CAPN1PYGLELANE | |
| SCHEMBL2797648 | 0.74 | CAPN1 (0.46) | CAPN1CCR1PYGL | |
| SCHEMBL2802814 | 0.72 | CAPN1 (0.67) | CAPN1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567325-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20150045394-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-12 | — | — | US | disclosed |
| US-8906941-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2398783-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-08-26 | — | — | US | disclosed |
| WO-2010094755-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045394-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAMK4, CAMK2A, CAMK2B | CAPN1 4/4885CCR1 3526/4885PYGL 417/4885 |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK4, CAMK2A, CAMK2B | CAPN1 4/4885CCR1 3576/4885PYGL 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.